HRTIS logo

Herantis Pharma Oyj Stock Price

HLSE:HRTIS Community·€51.3m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

HRTIS Share Price Performance

€0
-1.24 (-100.00%)
€0
-1.24 (-100.00%)
Price €0

HRTIS Community Narratives

There are no narratives available yet.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

7 Risks
0 Rewards

Herantis Pharma Oyj Key Details

€0

Revenue

€0

Cost of Revenue

€0

Gross Profit

€5.5m

Other Expenses

-€5.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.23
0%
0%
1.4%
View Full Analysis

About HRTIS

Founded
2008
Employees
13
CEO
Antti Vuolanto
WebsiteView website
herantis.com

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

Recent HRTIS News & Updates

Will Herantis Pharma Oyj (HEL:HRTIS) Spend Its Cash Wisely?

Oct 04
Will Herantis Pharma Oyj (HEL:HRTIS) Spend Its Cash Wisely?

Recent updates

No updates